Carlsmed to report Q2FY26 results on August 5, 2026

0 min read     Updated on 23 Jul 2026, 09:12 AM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Carlsmed will announce its second quarter 2026 financial results after market close on August 5, 2026. Management will host a conference call and webcast at 1:30 PM Pacific Time to discuss the quarterly performance.

powered bylight_fuzz_icon
46323712

*this image is generated using AI for illustrative purposes only.

Carlsmed, Inc. will announce its second quarter 2026 financial results after market close on August 5, 2026. The medical technology company, specializing in AI-enabled personalized spine surgery solutions, scheduled the release to provide updates on its operational progress. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time on the same day to discuss the quarterly performance.

Investors can access the live webcast through the Events & Presentations section of the company’s investor website at investors.carlsmed.com. Telephone participation is available by registering online in advance. A replay of the call will be archived on the company’s website following the event for those unable to attend the live session.

Conference Call Details

Event Details
Date August 5, 2026
Time 1:30 PM Pacific Time
Webcast investors.carlsmed.com
Telephone Registration Available online

What specific operational milestones does Carlsmed expect to highlight for Q2 2026?

How might the financial results impact investor sentiment toward AI-enabled medical technologies?

What market trends could influence Carlsmed's performance in the latter half of 2026?

like18
dislike

Needham initiates coverage on Carlsmed with Buy rating

0 min read     Updated on 01 Jul 2026, 07:50 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Needham analyst David Saxon has initiated coverage on Carlsmed with a Buy rating and a price target of $17. The company is listed on NASDAQ under the ticker CARL.

powered bylight_fuzz_icon
44461219

*this image is generated using AI for illustrative purposes only.

Needham analyst David Saxon has initiated coverage on Carlsmed with a Buy rating and a price target of $17. The rating reflects a positive outlook on the company's performance and market position.

Carlsmed is listed on NASDAQ under the ticker symbol CARL. The initiation of coverage provides a new valuation benchmark for investors tracking the stock.

Key Details

Metric Detail
Rating Buy
Price Target $17
Analyst David Saxon
Exchange NASDAQ
Ticker Symbol CARL

What upcoming clinical milestones could drive Carlsmed's stock performance toward the $17 price target?

How might competitor developments impact Carlsmed's market position and valuation?

What are the potential risks or challenges Carlsmed could face in the near term?

like17
dislike